Translational Oncology

Division of Translational Oncology

Prof. Dr. Christof von Kalle (currently on sabbatical leave)

The Division is deeply involved in the clinical activities of NCT and contributes to trial development, with a special focus on molecular diagnosis and therapy. Six physician scientists of the Division participate in patient care in outpatient clinics, tumor boards and clinical standard conferences and support diagnostic and therapeutic translation from DKFZ and HUMC into innovative clinical trials.

Outlook:
The Division will further develop its research focus in the field of normal and cancerous stem cell biology, insertional mutagenesis in cancer and gene therapeutic approaches. It aims to decipher mechanisms of tumor initiation, self-renewal, metastasis and heterogeneity of tumor-initiating cells and of step-wise malignant transformation in leukemogenesis. Assays for bulk and single-cell T- and B-cell receptor sequencing and bioinformatical analysis allow the identification of antigen-specific clones and the study of immune response dynamics in health and disease. Future clinical studies will include clonal monitoring of the T lymphocyte repertoire in immunotherapy and of gene corrected cells. Gene therapy vector characterization and eventual oncogenicity are also investigated to elucidate the role of genomic instability in carcinogenesis.

Contact

Prof. Dr. Christof von Kalle (currently on sabbatical leave)
Translational Oncology (G100)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 460
69120 Heidelberg
Tel: +49 6221 42 1608

Selected Publications

  • Weischenfeldt J, et al. (2017). Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nat Genet, 49(1):65-74.
  • Ruggiero E, et al. (2015). High-resolution analysis of the human T cell receptor repertoire. Nat Commun; 6:8081. DOI: 10.1038/ncomms9081.
  • Gabriel, R, et al. (2015). Mapping the precision of genome editing. Nat Biotechnol; 33(2):150-152.
  • Kaeppel C, et al. (2013). A largely random AAV integration profile after LPLD gene therapy. Nat Med; 19(7):889-91.
to top